Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I

Abstract Abstract 1733 Background: Patients with myelofibrosis (MF) suffer from cytopenias, debilitating symptoms, and splenomegaly, all of which may contribute to shortened life expectancy. Cachexia is a common manifestation of MF. Its causes are multifactorial and include elevated inflammatory cytokines and mechanical effects of splenomegaly. It is a predictor of poor survival in patients with MF. Cachexia manifests as weight loss with low body-mass index (BMI; <20–21 kg/m2) (Strasser F. Sixth Research Congress of the European Association of Palliative Care; Wagner PD. Eur Respir J. 2008;31:492–501) and with metabolic indicators of poor nutritional status including hypocholesterolemia (total cholesterol <150 mg/dL or <3.89 mmol/L), which has been linked to poor prognosis in MF (Mesa et al. Blood 2007;110:abstract 2548). In the phase III, placebo-controlled, COMFORT-I study, ruxolitinib treatment significantly reduced spleen volume, improved MF-related symptoms, and exhibited a survival advantage compared with placebo in patients with MF. In this post hoc analysis, we investigated the effects of ruxolitinib treatment on weight and total cholesterol and the association of these changes with survival in COMFORT-I. Methods: Eligible patients in COMFORT-I were randomized to receive placebo (n=154) or ruxolitinib (n=155) at starting doses of 15 and 20 mg PO BID depending on baseline platelet count. Body weight was measured at baseline, and weeks 4, 8, 12, 16, and 24 and then every 12 weeks thereafter. Total serum cholesterol was measured at baseline and weeks 4, 12, 24, and then every 24 weeks thereafter. All patients receiving PBO completed crossover or discontinued within 3 months of the primary data analysis (when all patients completed 24 weeks and when half the patients remaining on study completed 36 weeks of treatment); thus, data for these patients were available for up to week 36 for weight and week 24 for total cholesterol. Kaplan-Meier analyses of overall survival were conducted in patients randomized to ruxolitinib stratified into 2 groups based on the median values separately for maximum weight gain and for maximum increase in total cholesterol during randomized treatment. Results: At baseline, mean body weight was similar between the treatment groups (72 kg, both) and mean total cholesterol was low (<150 mg/dL) in both treatment groups (ruxolitinib: 118 mg/dL; placebo: 115 mg/dL). The proportion of patients with BMI <22 were similar between the treatment groups (ruxolitinib: 23%; placebo: 28%) as was the proportion with total cholesterol <150 mg/dL (82%, both). Patients randomized to ruxolitinib experienced a gradual increase in body weight that stabilized by week 36 of treatment whereas patients receiving placebo experienced decreases in body weight over time (Figure 1). Similarly, total cholesterol increased in patients randomized to ruxolitinib and decreased in patients receiving placebo (Figure 2). Although total cholesterol increased over time in ruxolitinib-treated patients, increases did not exceed the upper limit of normal (199 mg/dL or 5.15 mmol/L). Nearly all patients randomized to ruxolitinib experienced weight gain (96% of patients) or an increase in total cholesterol (97% of patients). In patients randomized to ruxolitinib, weight gain above the median was associated with prolonged survival relative to lesser degrees of weight gain (HR=0.40; 95% CI: 0.18, 0.90; P=0.022; Figure 3). Similarly, increase in total cholesterol above the median was also associated with prolonged survival relative to a lesser degree of total cholesterol increase (HR=0.46; 95% CI: 0.21, 1.01; P=0.048; Figure 4). Meaningful comparisons with the placebo group based on the same stratification criteria could not be conducted as the majority of such patients experienced weight loss and decreases in total cholesterol while on the study; however, overall survival favored both ruxolitinib groups relative to all patients randomized to placebo even for ruxolitinib-treated patients with lower than median levels of weight gain or increase in total cholesterol. Conclusions: Ruxolitinib therapy promotes weight gain and improves total cholesterol in MF patients. These results suggest that the survival advantage exhibited by ruxolitinib over placebo in MF patients may be partly explained by reversal of the catabolic state and cachexia. Disclosures: Mesa: Incyte: Research Funding; Lilly: Research Funding; Sanofi: Research Funding; NS Pharma: Research Funding; YM Bioscience: Research Funding. Verstovsek:Incyte Corporation: Research Funding. Gupta:Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; YM Biosciences: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi#x2610;#x0025; Aventis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Mascarenhas:Incyte Corporation: Consultancy; Novartis: Clinical Trial Support, Clinical Trial Support Other. Atallah:Incyte: Consultancy, Research Funding. Sun:Incyte Corporation: Employment, Equity Ownership. Sandor:Incyte Corporation: Employment, Equity Ownership. Gotlib:Incyte Corporation: Consultancy, Honoraria, Support for travel to meeting for the study or other purposes from Incyte Other.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.